Embecta Corp. (EMBC)
(Delayed Data from NSDQ)
$14.00 USD
+0.81 (6.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $14.02 +0.02 (0.14%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.00 USD
+0.81 (6.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $14.02 +0.02 (0.14%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth C Momentum C VGM
Zacks News
Embecta Corp. (EMBC) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 54.17% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 1.47% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Embecta Corp. (EMBC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Embecta Corp. (EMBC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Embecta Corp. (EMBC) stock based on the movements in the options market lately.
Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?
by Zacks Equity Research
Embecta Corp. (EMBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Best Value Stocks to Buy for May 15th
by Zacks Equity Research
CIXXF, JXN and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 15, 2024.
Cencora (COR) Q2 Earnings Top Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 4.11% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Value Stocks to Buy for February 12th
by Zacks Equity Research
XRX, EMBC and HMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 12, 2023.
Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 35.56% and 4.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 11.11% and 1.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Moves 13.2% Higher: Will This Strength Last?
by Zacks Equity Research
Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Ideas feature highlights: Beacon Roofing Supply, Embecta and Western Midstream Partners
by Zacks Equity Research
Beacon Roofing Supply, Embecta and Western Midstream Partners have been highlighted in this Investment Ideas article.
Time to Buy These Intriguing Additions to Zacks Rank #1 (Strong Buy) List
by Shaun Pruitt
Several intriguing stocks were recently added to the Zacks Rank #1 (Strong Buy) list this week and shouldn't be overlooked as we round out what has been an exciting year for the stock market.
Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 0% and 65.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Embecta Corp. (EMBC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -55.56% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 16th
by Zacks Equity Research
CURO, ELUXY and EMBC have been added to the Zacks Rank #5 (Strong Sell) List on October 16, 2023.
Embecta Corp. (EMBC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 50% and 4.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Avantor, Inc. (AVTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Embecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?